Eris Lifesciences Limited (NSE:ERIS)
India
· Delayed Price · Currency is INR | Market Cap | 174.13B |
| Revenue (ttm) | 27.24B |
| Net Income (ttm) | 3.29B |
| Shares Out | 136.13M |
| EPS (ttm) | 24.18 |
| PE Ratio | 52.90 |
| Forward PE | 35.01 |
| Dividend | 7.35 (0.57%) |
| Ex-Dividend Date | Feb 13, 2025 |
| Volume | 66,309 |
| Average Volume | 311,482 |
| Open | 1,275.85 |
| Previous Close | 1,275.85 |
| Day's Range | 1,260.00 - 1,300.95 |
| 52-Week Range | 809.15 - 1,593.90 |
| Beta | 0.34 |
| RSI | 48.38 |
| Earnings Date | May 23, 2025 |
About Eris Lifesciences
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measureme... [Read more]
Financial Performance
In 2023, Eris Lifesciences's revenue was 19.91 billion, an increase of 19.83% compared to the previous year's 16.62 billion. Earnings were 3.92 billion, an increase of 2.57%.
Financial StatementsNews
Eris Lifesciences shares drop 4% as net profit dips 14.3% YoY in Q3
Eris Lifesciences shares declined by 4% after the company announced its Q3 FY25 financial results. Despite strong revenue growth, profitability took a hit due to rising expenses. As of 1:04 AM, the sh...
Eris Lifesciences Q3 FY25 Results: Revenue up 49.6% YoY to Rs 727.45 crore, Net profit dips 14.3%
Eris Lifesciences reported its Q3 FY25 financial results, showcasing strong revenue growth but a decline in net profit due to higher expenses. The company’s revenue from operations surged to ₹727.45 c...
Eris Lifesciences Q2 results: Revenue rises 46.7% YoY to ₹741.17 crore, Net Profit falls 21.2% YoY
Eris Lifesciences has reported its financial results for the second quarter of FY24, showcasing significant year-on-year growth in net revenue, while net profit has seen a decline both year-on-year an...
Market movers: BSE rises 6.90%, JP Power up 4.96%, JSW Steel gains 1.98%, Jindal Steel climbs 2.43%, Eris Lifesciences up 3.56%, Just Dial adds 2.53% among key gainers
The Indian stock market saw strong early trading action today, with several key stocks experiencing significant price movements across various sectors: BSE Ltd. emerged as one of the top gainers, surg...
Eris Lifesciences stock up 3.24%, sees ₹270.76 crore block deal as 2 million shares change hands
Eris Lifesciences shares jumped by 3.24% to ₹1,367.20 in early trading following a block deal worth ₹270.76 crore on the NSE. A total of 2,004,438 shares were traded at ₹1,350.80 per share during the ...
ChrysCapital sells entire stake in Eris Lifesciences for ₹1,187 Crore
Private equity firm ChrysCapital has exited its investment in Eris Lifesciences by selling its entire 7.27% stake in the company for ₹1,187 crore. The stake was purchased by Infinity Partners through ...
Eris Lifesciences sees 7.2% equity change hands in ₹1,187 crore block deal
Eris Lifesciences witnessed a substantial block deal on August 22, with approximately 98.9 lakh shares, representing 7.27% of its equity, changing hands for ₹1,201 per share, totaling ₹1,187 crore. De...